Context Therapeutics (NASDAQ:CNTX) Lowered to “Sell” Rating by Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Other equities analysts have also issued reports about the stock. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Piper Sandler boosted their target price on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. JonesTrading started coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.60.

Context Therapeutics Trading Up 2.0%

Shares of NASDAQ:CNTX opened at $2.59 on Friday. The business has a 50-day moving average price of $2.48 and a 200 day moving average price of $1.63. The company has a market capitalization of $237.97 million, a price-to-earnings ratio of -6.82 and a beta of 1.96. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). As a group, equities research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently added to or reduced their stakes in CNTX. Millennium Management LLC purchased a new stake in Context Therapeutics during the 4th quarter worth approximately $3,824,000. Marshall Wace LLP boosted its position in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares during the period. Renaissance Technologies LLC grew its stake in shares of Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after acquiring an additional 188,202 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the third quarter worth $100,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics News Summary

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a “Strong‑Buy” rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.